# Microbiota Transplantation as a Future Novel Therapeutic Strategy Approach

## TL;DR

This paper explores vaginal microbiome transplantation as a new treatment for bacterial vaginosis, highlighting its potential and challenges.

## Contribution

The paper introduces precision-based therapeutic strategies for bacterial vaginosis inspired by microbiota transplantation successes.

## Key findings

- VMT shows potential as an alternative to antibiotics for treating bacterial vaginosis.
- Treatment outcomes vary significantly between individuals due to genetic and microbial factors.
- Personalized interventions are needed to improve VMT efficacy.

## Abstract

Bacterial vaginosis (BV) is a leading cause of genital discomfort among women globally, and it arises from dysbiosis of the vaginal ecosystem characterized by the overgrowth of pathogenic bacteria. Current therapeutic strategies primarily rely on antibiotics and/or probiotics, which demonstrate clinical efficacy but are frequently associated with limitations such as antimicrobial resistance, high recurrence rates, and incomplete restoration of a healthy vaginal microbiota. Inspired by the success of fecal microbiota transplantation in gastrointestinal disorders, vaginal microbiome transplantation (VMT) from healthy donors has emerged as a potential alternative therapeutic approach for BV. However, experimental and early clinical studies indicate that VMT efficacy is not uniform across individuals, with considerable inter-individual variability in treatment outcomes. Host genetic factors, baseline vaginal microbial composition, immune status, and environmental influences are likely to modulate therapeutic success, underscoring the need for personalized interventions. This article critically evaluates the shortcomings of existing standardized treatments, highlights the potential advantages and challenges of VMT, and discusses emerging, precision-based therapeutic strategies for BV in light of recent research advances and ongoing clinical trials worldwide.